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Abstract: Celiac disease (CD) is a gluten-dependent autoimmune disorder affecting a significant
percentage of the general population, with increasing incidence particularly for children. Reliable
analytical methods suitable for the serological diagnosis of the disorder are urgently required for
performing both the early diagnosis and the follow-up of a patient adhering to a gluten-free diet.
Herein we report on the preparation and application of a novel electrochemical immunosensor
based on the use of ensembles of gold nanoelectrodes (NEEs) for the detection of anti-tissue
transglutaminase (anti-tTG), which is considered one reliable serological marker for CD. To this end,
we take advantage of the composite nature of the nanostructured surface of membrane-templated
NEEs by functionalizing the polycarbonate surface of the track-etched membrane with tissue
transglutaminase. Incubation of the functionalized NEE in anti-tTG samples results in the capture
of the anti-tTG antibody. Confirmation of the recognition event is achieved by incubating the NEE
with a secondary antibody labelled with horseradish peroxidase (HRP): in the presence of H2O2 as
substrate and hydroquinone as redox mediator, an electrocatalytic current is indeed generated whose
increment is proportional to the amount of anti-tTG captured from the sample. The optimized sensor
allows a detection limit of 1.8 ng mL−1, with satisfactory selectivity and reproducibility. Analysis
of serum samples from 28 individuals, some healthy and some affected by CD, furnished analytical
results comparable with those achieved by classical fluoroenzyme immunoassay (FEIA). We note
that the NEE-based immunosensor developed here detects the IgG isotype of anti-tTG, while FEIA
detects the IgA isotype, which is not a suitable diagnostic marker for IgA-deficient patients.
Keywords: celiac disease; immunosensor; anti-tissue transglutaminase; nanoelectrode array;
voltammetry
1. Introduction
Celiac disease (CD) is a gluten-dependent autoimmune disorder affecting approximately 1%
of the general population [1,2]. The only treatment that reduces mortality and the development
of CD-associated disorders is a gluten-free diet [3]. However, some patients can be asymptomatic
for years, so in the absence of suitable diagnostic tools, the disease diagnosis can be dangerously
postponed. Up to a few years ago, definitive diagnosis of CD was based on detecting histological
changes in small intestinal mucosa after biopsy. However, recent guidelines by the European Society
of Pediatric Gastroenterology advise against intestinal biopsy in symptomatic CD patients with
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high serum concentrations of anti-tissue transglutaminase (anti-tTG) antibodies (10 times the cut-off
value) [4,5].
Currently, CD-related antibodies are investigated by using optical ELISA, fluoroenzyme
immunoassay (FEIA), or indirect immunofluorescence assay [6,7]. Immunoglobulin A (IgA) is the
isotype typically determined as the target analyte for serological CD screening, but IgA-deficient
CD patients are not identified by IgA serology; in these patients, immunoglobulin G (IgG) anti-tTG
antibodies are investigated [8]. However, several clinical studies have shown that IgG anti-tTG
antibodies are not as sensitive and specific as the IgA anti-tTG antibodies, and the use of the indirect
immunofluorescence assay to detect anti-endomysium antibodies (EMA) in daily practice is limited
by subjective interpretations [9]. The cut-off value for IgG anti-tTG antibodies measurement is
7 U/mL. This evidence indicates that the development of an IgG-based diagnostic method with
improved sensitivity and specificity is urgently required. Many trials have been conducted to develop
anti-tTG electrochemical sensors using different approaches to improve the analytical performances
of functionalized electrode surfaces [10–16]; however, up to now, no unique confirmatory serological
electrochemical biosensor has been adopted for practical use.
Recent studies [17] demonstrated that the analytical performances of bioelectrochemical sensors
can be improved by miniaturization of the transduction element down to the nanometer scale; this
results in a dramatic enhancement of diffusive mass fluxes to the nanoelectrode as well as a lowering
of the double-layer charging current, with both factors contributing to dramatic improvements in
detection limits [18–29]. Moreover, unlike with the use of an individual nanoelectrode, arrays of
nanoelectrodes do not require high amplification of current signals nor the use of shielding devices
such as a Faraday cage. Arrays indeed provide higher faradaic currents, along with significant
improvements to the accuracy and precision [27–31]. Arrays of nanoelectrodes can be fabricated with
an ordered spatial distribution or with a random distribution to obtain the so-called nanoelectrode
ensembles (NEEs) [22,27,32–34].
In this work, we employ NEEs prepared via template electroless deposition of gold within the
pores of polycarbonate (PC) track-etched membranes [22,32]. When the boundaries of the radial
diffusion layers of each nanoelectrode overlap, the so-called total overlap (TO) diffusion regime is
achieved [22,34]. NEEs prepared from commercially available track-etched PC membranes (typically
with an average pore diameter of 30 nm, average pore distance of 200 nm, and pore density of
6 × 108 pores/cm2) operate under the TO regime, providing peak-shaped voltammetric signals.
The faradaic peak current is proportional to the geometric area (Ageom, that is, the area of the
nanoelectrodes and the insulator between them exposed to the electrolyte), while the double-layer
charging current depends only on the active area (Aact, i.e., the area of the metal nanoelectrodes only).
Typically, for NEEs, the Ageom/Aact ratio (that is, the reciprocal of the fractional area, f ) is of the order
of 102–103, allowing one to achieve detection limits 2–3 orders of magnitude lower than those obtained
with millimeter-sized electrodes with the same geometric area [22,33]. For biosensing purposes, an
additional advantage of NEEs is the possibility of binding biomacromolecules (proteins or DNA) onto
the PC membrane used to prepare the nanoelectrode ensemble [27]. The surface of the PC membrane
contains a significant surface concentration of pendant carboxylic groups, which can interact with the
amino terminations of the biomolecules [35,36]. Several biosensors have been recently developed using
this strategy for detecting DNA [37], proteins [38–40], or enzyme substrates [41]. In the present work,
we take advantage of the potentialities offered by NEEs by developing an anti-tTG electrochemical
sensor, the architecture of which is summarized in Scheme 1.
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Scheme 1. Scheme depicting the immunosensor architecture and the associated electrochemical and 
enzymatic processes, where PC= polycarbonate; tTG= tissue transglutaminase; Anti-tTG= antibody 
for tissue transglutaminase; HRP= horseradish peroxidase; H2Q= hydroquinone; BQ= benzoquinone. 
Components are not drawn to scale; the average diameter of the Au nanoelectrodes is 30 nm and 
their average center-to-center distance is 200 nm. 
The biorecogniton element is composed of molecules of the tTG antigen adsorbed onto the PC 
which surrounds the nanoelectrodes. It captures the target analyte, namely, anti-tTG, which is then 
reacted with a secondary antibody labelled with HRP. Finally, the binding of HRP is detected by 
adding H2O2 as substrate and hydroquinone (H2Q) as redox mediator, thus modulating, via the 
electrochemical reduction of benzoquinone (BQ), the enzymatic reduction of H2O2 by HRP. It is 
worth noting that our group recently applied a similar NEE-based architecture in the development 
of a novel immunosensor for the detection of anti-tTG [42] which employs 
electrochemiluminescence (ECL) as the detection technique. ECL indeed allows us to achieve high 
sensitivity and very low detection limits (for anti-tTG as low as 470 pg/mL [42]); however, it 
requires the use of a quite complex sensor architecture in which a biotinilated secondary Ab is 
bound to a streptavidin-modified ruthenium label, generating ECL by reaction with a co-reactant, 
namely, tri-propylamine [42]. In the electrochemical (EC) sensor studied here, the use of 
voltammetry as the detection technique allowed us to exploit a simpler and more conventional 
sensor architecture based on the use of HRP-labeled goat anti-human IgG as the secondary 
antibody (see Scheme 1). In the present work, after detailed characterization of the sensor and 
optimization of its analytical performances, special focus is put in demonstrating its possible use for 
diagnostics purposes in human serum samples by analyzing anti-tTG in serum samples from 28 
pediatric patients and comparing the sensors’ responses with results obtained using existing 
analytical methods.  
2. Experiment Details 
2.1. Instrumentation 
Cyclic voltammetry (CV) was performed with a CHI 660B potentiostat using a three-electrode 
electrochemical cell where the NEE was the working electrode, a Pt spiral was the counter 
electrode, and Ag/AgCl, KCl saturated was the reference electrode. 
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2. Experiment Details
2.1. Instrumentation
Cyclic voltammetry (CV) was performed with a CHI 660B potentiostat using a three-electrode
electrochemical cell where the NEE was the working electrode, a Pt spiral was the counter electrode,
and Ag/AgCl, KCl saturated was the reference electrode.
Sensors 2019, 19, 1233 4 of 16
Scanning electron microscopy (SEM) and energy-dispersive X-ray spectroscopy (EDS) analysis
were performed using a TM3000 Hitachi tabletop scanning electron microscope coupled with a
SwiftED3000 X-Ray microanalysis system.
2.2. Chemicals and Materials
Gold electroless plating solution (Oromerse Part B, Technic Inc., Cranston, RI, USA), bovine serum
albumin (BSA), Tween 20, hydrogen peroxide 30%, and hydroquinone (H2Q) 99% were purchased
from Sigma. Buffer solutions, carbonate–bicarbonate buffer pH 9.2, 0.01 M phosphate buffer saline
(PBS) pH 7.4, and 0.05 M phosphate buffer (PB) pH 7.4 were prepared with distilled water. All other
reagents were of analytical grade.
Human recombinant tissue transglutaminase (h-tTG) was prepared as previously described [1].
Monoclonal mouse anti-human tTG antibody (CUB 7402) was purchased from BioOptica, HRP-labeled
goat anti-human IgG (whole molecule) from Sigma-Aldrich, and HRP-labeled goat anti-mouse pAb
IgG secondary antibody from Abcam. All serum samples were from pediatric patients aged between
2 and 16 years and were supplied by Burlo Garofolo Pediatric Institute (Trieste, Italy); the ethical
committee assurance number is CE/V-131. All the biologicals including BSA and Tween 20 were
diluted using 0.01 M PBS pH 7.4.
Track-etched PC filter membrane (47 mm overall filter diameter, 6 µm thickness, impregnated by
the producer with polyvinylpyrrolidone) with an average pore diameter of 30 nm and pore density of
600 million pores per cm2 from SPI supplies (West Chester, PA, USA) was used as a template for the
preparation of the nanoelectrode ensembles.
2.3. Methods
2.3.1. Fabrication of the NEEs
NEEs were prepared by electroless deposition of gold in track-etched PC filter membranes
using an already published procedure [22] and its following updates [32,36]. During the electroless
deposition of gold from a solution, each pore of the PC membrane was filled with a metal nanowire
whose head was exposed to the electrolyte solution so that the surface of the NEE was composed of
millions of randomly spaced gold nanodisks. The membrane bearing the nanodisks was assembled
into electrodes of suitable geometry and size as previously described [34]. Typical values for Ageom
and Aact for the NEEs used in this work were 7 × 10−2 cm2 and 6 × 10−4 cm2, respectively.
2.3.2. Immunosensor Construction and Electrochemical Detection
An aliquot of 10 µL of 10 µg mL−1 tTG solution in 0.1 M carbonate buffer, pH 9.2, was dropped on
the NEE and incubated for 2 h at 25 ◦C to obtain what we will call here TGNEE. It has been previously
shown that under these conditions, antigen and antibody proteins bind preferentially on the PC of
NEEs [38–42]. The TGNEE was subsequently blocked with 1% BSA in 0.01 M PBS, pH 7.4, for 30 min,
followed by incubation for 60 min with 10 µL standard solution of anti-tTG or serum sample, diluted
1:200 with 0.01 M PBS, pH 7.4 (unless differently indicated). After washing with 0.01 M PBS, pH 7.4,
containing 0.05% Tween 20, the captured primary antibody was coupled with 20 µL of 10 µg mL−1
HRP-labeled goat anti-mouse IgG secondary antibody in 0.01 M PBS, pH 7.4, for 60 min. Incubations
were carried out at room temperature (22 ± 1 ◦C) in a water-vapor-saturated vessel. All washing
procedures were followed by gentle drying with N2 flow. Finally, the immunosensor was dipped in
an electrochemical cell containing freshly prepared 1 mM H2Q in 0.05 M phosphate buffer (pH 7.4).
The H2Q solution was prepared under N2 in an amber glass bottle to avoid oxidation by atmospheric
O2 and light. All electrochemical measurements were performed at room temperature in an electrolyte
solution deoxygenated with N2. Cyclic voltammograms were recorded before and after addition of
1.5 mM H2O2 at scan rate of 50 mV s−1 between −0.65 and +0.85 V. Negative controls were performed
in the absence of anti-tTG.
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Fluoroenzyme immunoassay for anti-tissue transglutaminase antibodies was performed according
to the manufacturer’s instructions (EliaTM Celikey, Phadia 250).
3. Results and Discussion
Figure 1A (dashed line) shows the cyclic voltammogram recorded with a bare NEE in 1 mM
H2Q, 0.5 M PBS (pH 7.4). It is characterized by a reduction peak at −0.27 V to which an oxidation
peak at 0.64 V is associated, with both peak currents scaling linearly with the H2Q concentration (in
the range 1–5 mM) and the square root of the scan rate (in the range 20–200 mV s−1, not shown).
The full line CV in Figure 1A shows that the addition of 1.5 mM H2O2 does not cause any significant
change in the voltammetric pattern, thus excluding the occurrence of any direct reaction between
H2Q and H2O2 in these experimental conditions. These results agree with the previous literature
for macroelectrodes [43–51] which attributed the observed CV signals to the 2-electrons/2-protons
electrochemical oxidation of H2Q to BQ and following re-reduction, according to reaction (1) and
Scheme 2:
H2Q→ BQ + 2 e + 2 H+ (1)
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Indeed, the forward-to-backward peak separation observed with the NEE is quite large 
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On the contrary, the full line CV in Figure 1B shows that a dramatic change is detected with 
the TGNEE–antiTG–secAb-HRP electrode system when 1.5 mM H2O2 is added to the electrolyte 
solution. A sharp increase of the reduction current with a slight shift in peak potential to −0.35 V is 
detected, the peak tending to acquire a partially sigmoidal profile. Note that, concomitantly, the re-
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perfectly reversible. The large peak-to-peak separation observed ith the EE agrees ith the fact
that these electrode arrays behave as electrodes with a partially blocked surface (PBSEs) [22,33,52–56],
where the nanodisk electrodes of the NEEs correspond to the unblocked surfaces of the PBSE, while
the PC template is the blocking material [22]. Therefore, the kinetics of heterogeneous electron transfer
are apparently slowed down by a factor that depends on fractional area, such that redox systems
which are quasi-reversible in nature (e.g., H2Q) behave as electrochemically irreversible systems at
NEEs [22,33].
Figure 1B reports the CV patterns recorded for 1 mM H2Q with a TGNEE, incubated at
first with anti-tTG and then with secAb-HRP (see Section 2 for details), from here on named
tTGNEE–anti-tTG–secAb-HRP. The dashed and full line CVs refer to volta mograms recorded in the
absence and presence of 1.5 2 , respectively.
The for er CV pattern (Figure 1B, dashed line) is similar with the one recorded with a bare NEE
(Figure 1A, dashed line), indicating that the functionalization of the NEE does not interfere with the
electron transfer.
n the contrary, the full line CV in Figure 1B shows that a dramatic change is detected with the
TGNEE–antiTG–secAb-HRP electrode system when 1.5 mM H2O2 is added to the electrolyte solution.
A sharp increase of the reduction current with a slight shift in peak potential to −0.35 V is detected,
the peak tending to acquire a partially sigmoidal profile. Note that, concomitantly, the re-oxidation
peak at +0.64 V disappears.
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Figure 1. Cyclic voltammograms recorded at 50 mV s−1 in 1 mM H2Q, 0.05 M PBS (pH 7.4) (A) with a 
bare nanoelectrode ensemble (NEE) before (dashed line) and after (solid line) the addition of 1.5 mM 
H2O2; and (B) with a NEE functionalized with transglutaminase incubated with anti-tTG and then 
with secAb-HRP (i.e., TGNEE–antiTG–secAb-HRP), before (dashed line) and after (solid line) the 
addition of 1.5 mM H2O2. 
The above experimental evidence supports the hypothesis of the occurrence at the TGNEE–
antiTG–secAb-HRP sensor of the following enzyme-mediated electrocatalytic cycle: 
BQ + 2 e + 2 H+ → H2Q (2) 
H2O2 + HRP (Fe3+) → HRP(Fe4+ = O) + H2O (3) 
HRP(Fe4+ = O) + H2Q → HRP(Fe3+) + H2O + BQ. (4) 
Reaction (3) between the oxidized HRP label and H2Q agrees with the observed increase of the 
cathodic peak current associated with Reaction (1) as well as with the disappearance of the 
oxidation peak at +0.7 V, since H2Q is continuously reoxidized chemically rather than 
electrochemically. 
All this evidence confirms the efficiency of the biorecognition–detection approach described in 
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Figure 1. Cyclic voltammograms recorded at 50 mV s−1 in 1 mM H2Q, 0.05 M PBS (pH 7.4) (A) with a
bare nanoelectrode ensemble (NEE) before (dashed line) and after (solid line) the addition of 1.5 mM
H2O2; and (B) with a NEE functionaliz d with transglutami ase incubated with anti-tTG a d then with
secAb-HRP (i.e., TGNE –antiTG–secAb-HRP), before (dashed line) and after (solid line) the additio
of 1.5 mM H2O2.
The above experimental evidence supports the hypothesis of the occurrence at the
TGNEE–antiTG–secAb-HRP s nsor of the following enzyme-mediated ele trocatalytic cycle:
BQ + 2 e + 2 H+ → H2Q (2)
H2O2 + HRP (Fe3+)→ HRP(Fe4+ = O) + H2O (3)
HRP(Fe4+ = O) + H2Q→ HRP(Fe3+) + H2O + BQ. (4)
Reaction (3) between the oxidized HRP label and H2Q agrees with the observed increase of the cathodic
peak current associated with Reaction (1) as well as with the disappearance of the oxidation peak at
+0.7 V, since H2Q is continuously reoxidized chemically rather than electrochemically.
All this evidence confirms the efficiency of the biorecognition–detection approach described in
Scheme 1.
3.1. Optimization of Signal Detection Parameters
To optimize the immunosensor response, the role of the concentration of the enzyme substrate
H2O2 and the mediator H2Q was studied while keeping the concentration of the anti-tTG in the
incubation bath constant at 1 µg mL−1.
Figure 2A shows the changes in the CVs obtained with the TGNEE–AntiTG–secAb-HRP for
H2O2 concentrations in the range 0–2.5 mM at constant H2Q concentration (namely, 1.0 mM).
The electrocatalytic current shows a slight increase with the hydrogen peroxide concentration up
to 1.5 mM. For H2O2 concentrations of >1.5 mM, the correct evaluation of Icat was hampered by the
rise in a sloping background current which is probably related to the electrochemical reduction of
excess H2O2 [57,58]. Figure 2B reports the effect of the concentration of the redox mediator (at constant
H2O2) on the cyclic voltammograms. The cathodic peak current increases with the concentration of
H2Q up to 1 mM, levelling off for higher mediator concentrations and showing a saturation trend
typical for mediated electrochemical processes. Based on these results, 1.5 mM H2O2 and 1.0 mM H2Q
were chosen as the most suitable substrate and mediator concentrations for continuing the study.
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Figure 2. Cyclic voltammograms recorded at 50 mV s−1 with deoxygenated 0.05 M PBS (pH 7.4) 
containing (A) 1 mM H2Q and 0.0, 0.5, 1.0, 1.5, 2.5 mM H2O2; or (B) 1.5 mM H2O2 and 1.0, 1.5, 1.75, 
2.0, 2.25 mM H2Q. 
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based on the effect of the enzymatic Reaction (3) on the electrochemical reduction of BQ, we 
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Figure 3. Continuous scan CVs recorded at 50 mV s−1 with the tTGNEE–Anti-tTG–secAb-HRP in 1 
mM H2Q, 0.05 M PBS (pH 7.4) before (dash line) and after (solid lines) addition of 1.5 mM H2O2: (A) 
in the potential window −0.65 to 0.90 V, initial potential 0.0 V, initial scan direction: positive; (B) in 
the potential window −0.65 to 0.20 V, initial potential 0.20 V, initial scan direction: negative. 
Figure 4 reports the calibration plots for the two approaches, obtained by incubating the 
TGNEE in tTG solutions prepared by serial dilutions of anti-tTG standards (Figure 3), followed by 
incubation with 20 µL of 10 µg mL−1 secAb-HRP. 
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containing ( ) 1 mM H2Q and 0.0, 0.5, 1.0, 1.5, 2.5 mM H2O ; or (B) 1.5 mM H2O2 and 1.0, 1.5, 1.75, 2.0,
2.25 mM H2Q.
The effects of the scanning potential window and direction of the sweep on the CV responses of the
immunosensor were also studied. Since the signal detection strategy in the immunosensor is based on
the effect of the enzymatic Reaction (3) on the electrochemical reduction of BQ, we focused on the role of
the width and initial direction of the voltammetric scan, which we performed in two alternative ways:
(A) in the potential window −0.65 to 0.90 V, initial potential 0.0 V, and initial scan direction: positive;
(B) in the potential window −0.65 to 0.20 V, initial potential 0.20 V, initial scan direction: negative.
Typical voltammograms recorded under these conditions with the TGNEE–antiTG–secAb-HRP sensor,
with and without H2O2 in the electrolyte, are illustrated in Figure 3A,B.
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Figure 3. Continuous scan CVs recorded at 50 mV s−1 with the tTGNEE–Anti-tTG–secAb-HRP in 1
mM H2Q, 0.05 M PBS (pH 7.4) before (dash line) and after (solid lines) addition of 1.5 mM H2O2: (A) in
the potential window −0.65 to 0.90 V, initial potential 0.0 V, initial scan direction: positive; (B) in the
potential window −0.65 to 0.20 V, initial potential 0.20 V, initial scan direction: negative.
Figure 4 reports the calibration plots for the two approaches, obtained by incubating the TGNEE
in tTG solutions prepared by serial dilutions of anti-tTG standards (Figure 3), followed by incubation
with 20 µL of 10 µg mL−1 secAb-HRP.
Approach (A) was preferred since it provides better sensitivity (see the slopes of the calibration
plots in Figure 4) and better reproducibility on repeated voltammetric scans (see Figure 3). Moreover,
the possibility to observe the decrease or disappearance of the anodic peak related to Reaction (1) offers
a direct experimental proof of the occurrence of the enzymatic process, thus providing qualitative
evidence of a positive response in the case of a successful biorecognition event. Therefore, the potential
window applied in all the following measurements was the one defined in approach A.
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It can be pointed out that experiments performed in the absence of anti-tTG indicate a lack of
e ectrocatalytic sign l in the CVs rec rded under such conditions. These tests gave similar results
when p formed in serum samples of althy individuals (s e below for details on the p ocedure),
thus c firming the effici ncy of the blocking with 1% BSA in avoiding undesired nonspecific binding
as false positives.
3.2. Analytical Performances
The dependence of the detected catalytic peak current signal at the immu osensor on the
anti-tTG concentration was studied over a wide antibody concentration range (0.001 to 10 µg mL−1).
T e experiments were perfor ed in triplicate by incubating different TGNEEs with serial dilutions
of monoclonal standard mouse anti-tTG. The CV responses of four representative concentrations are
reported in Figure 5.
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Figure 5. Cyclic volta ra s rec r e it t e T EE incubated with different concentrations of
anti-tTG (0, 0. 05, 0. 1, 0.1, and 1 µg mL−1); other conditions as in Figure 1A.
As shown in Figure 6A, the I values increase with the concentration of the anti-tTG (Canti-tTG),
tending to an asymptotic profile for concentrations greater than 1 µg mL−1; however, a linear trend
(R2 = 0.990) can be identified for concentrations of ≤1.0 µg mL−1 (see Figure 5B).
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Figure 6. Dependence of the voltammetric current at−0.35 V on the anti-tTG concentration: (A) 0.00–10 µg
mL−1; (B) 0.005–1.0 µg mL−1. Error bars indicate standard deviations of triplicate measurements (n = 3).
The precision (reproducibility) of the method was evaluated as the relative standard deviation
(RSD) of repeat d measurements (n = 10) performed with 0.5 µg mL−1 an -tTG; the result was 2.6%.
The detecti n limit (DL) was evaluated using the S/N = 3 criterion. In particular, the DL as calculated
as DL = 3(SD/m), where SD is the standard deviation of the y-axis intercept and “m” is the slope
(sensitivity) of the regression line, giving a result of 1.8 ng mL−1. The low detection limit, the wide
linear range, and excellent reproducibility indicate that the TGNEE immunosensor offers analytical
performances that are competitive with those achievable by other electroanalytical sensors developed
for the same goals [11–14]. On the other hand, we wish to point out that the ECL sensor developed
recently is characterized by a slightly lower detection limit (0.47 ng mL−1 vs. 1.8 ng mL−1), wider
linear range, and higher sensitivity; however, it has he disadvantage of relying on a more complex
analytic l pr cedure and the use of m r sophisticated and expensive equipm nt [42].
Trials of regenerating the NEEs from already-used immunosensors furnished unsatisfactory
results; therefore, each analyte solution was analyzed using a different TGNEE. In order to evaluate the
reproducibility between different NE-based sensors, the anti-tTG level in a standard analyte solution
was determined using three different NEE immunosensors. The standard deviation of this inter-assay
(n = 3) was 7% when using 1 µg mL−1 anti-tTG as the reference analyte concentration.
In order to study the stability of the immunosensor in storage, repeated determinations of
1 µg mL−1 anti-tTG were performed over a period of 7 days. The storage stability of the immunosensor
was investigated by measuring he im unosensors’ catalytic current response ve y other day. When
the immunosensor was not i use, it st red in 0.01 M PBS, pH 7.4, at 4 ◦C. The observed loss in
sensitivity was 5% on Day 3 and 25% on Day 7 after the preparation of the sensor. These results suggest
that the immunosensor can be stored for only a few days after the immobilization of tTG. Anyhow,
preparing fresh TGNEEs is not a main problem since it requires the simple incubation of an NEE (or a
set of NEEs) in 0.1 M carbonate buffer, pH 9.2, containing tTG (10 µg mL−1), as described in Section 2.
3.3. Analysis of Clinical Serum Samples
The feasibility of the proposed immunosensor for clinical applications was evaluated by analyzing
the anti-tTG IgG level of 28 clinical serum samples from pediatric patients aged between 2 and 16 years.
Out of the 28 serum samples, 23 were taken from patients with a confirmed CD diagnosis, whereas
the other 5 were taken from healthy individuals. The anti-tTG IgA levels of the CD positive samples
ranged from 16 to 776 U mL−1 (see Table 1, as determined by FEIA).
In order to set the optimum dilution of the serum samples, preliminary investigations were
performed at 1:10, 1:50, 1:100, and 1:200 dilution ratios with 0.01 M PBS, pH 7.4. The 1:200 dilution
was chosen for the analysis of all the serum samples due to its better catalytic peak current signal.
It is worth noting that the dilution minimizes possible interference from other proteins present in the
matrix [14].
Sensors 2019, 19, 1233 10 of 16
Figure 7 compares the different signals recorded when analyzing the serum of non-celiac
(Figure 7A) vs. celiac patients (Figure 7B), where the dashed and full line CVs were recorded in
the absence and presence of H2O2, respectively. The latter CVs indicate that a relevant catalytic current
increase is observed for the celiac patient’s sample, while a significantly smaller, almost negligible
effect is observed for the healthy subject’s one. Quantification of signals based on the increase in the
catalytic peak current was performed by interpolation with the calibration plot reported in Figure 6.
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Figure 7. Cyclic voltammetric responses of serum samples recorded at 50 mV s−1 with the proposed
immunosensor in 0.05 M PBS (pH 7.4) containing freshly prepared 1 mM H2Q before (dashed lines)
and after (solid lines) addition of 1.5 mM H2O2: (A) serum sample from healthy subject (sample 10691),
(B) serum sample from celiac patient (sample 10636).
Table 1 lists the final concentrations in serum of anti-tTG IgG determined by the electrochemical
immunosensor (EC-IS) for all the 28 serum samples analyzed, taking into account the 1:200 dilution
factor. They show that IgG data, measured by EC-IS, follow a trend parallel to that of the IgA values
obtained by FEIA; however, the IgG concentrations are one order of magnitude smaller than the
IgA concentrations.
Table 1. Average anti-tTG IgG and IgA concentrations determined by the proposed electrochemical
immunosensor (EC-IS) and clinical fluoroenzyme immunoassay (FEIA) methods, respectively.
Serum Sample
Anti-tTG
IgG (µg/mL)
by EC-IS
Anti-tTG
IgA (U/mL) by
FEIA
Serum Sample
Anti-tTG
IgG (µg/mL)
by EC-IS
Anti-tTG
IgA (U/mL) by
FEIA
10,669 41.3 366 10,644 * 13.22 0.1
10,658 15.855 232 10,550 27.28 420
10,636 37.08 442 10, 26 36.34 425
10,668 1.405 112 10,525 0 16
10,637 17.12 68 10,521 2.15 41
10,650 22.4 273 10,519 1.75 39
10,623 12.06 165 10,633 47.88 776
10,607 0 57 10,645 * 0 0
10,603 14.14 238 10,691 * 0 0
10,605 7.68 116 9830 10.22 128
10,562 29.58 81 9777 25.54 200
10,577 20.06 80 9597 * 0 0
10,594 25.3 643 9463 * 0 0
10,554 20.38 334 9784 4.42 100
* Samples where clinical reports indicated absence of CD (healthy).
Sensors 2019, 19, 1233 11 of 16
In order to evaluate the correlation quantitatively, statistical treatment was performed and the
Spearman’s (rs) and Pearson’s (r) coefficients were calculated. The relevant plot is shown in Figure 8.
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Figure 8. Scattered plot of normalized concentrations determined in real clinical serum samples
obtained by the proposed electrochemical immunosensor (EC-IS) vs. the standard fluoroenzyme
immunoassay (FEIA). Spearman’s coefficient (rs) of 0.84 and Pearson’s correlation (r) of 0.66 were
obtained. Both data sets are normalized with respect to the higher concentration measured.
The Spearman’s correlation (rs) is an important statistical parameter that measures the strength
of a monotonic relationship between paired data sets [59]. The Pearson’s coefficient (r), on the other
hand, quantifi s the reliability of the existence of a linear relationship between the two data sets. In the
case of satisfact ry corr lation, the valu s of the two correlation coefficie ts should range between 1
and −1.
From our results, the calculated the Spearman’s correlation coefficient to be 0.84 (>0.8), indicating
a very strong correlation b twe n the two data sets. The Pearson co fficient is 0.66, showing a strong
positive linear relationship between the r sults of th two methods.
Besides the strong agreement between the IgG level measured using the new method and the
corresponding IgA level determined by the clinical FEIA method, a preliminary set of experiments
was conducted on a few s rum sampl s to compare IgG data easured using our electrochemical
immunosensor and that using FEIA. To this end, the IgG activity was measured in the same samples
both by FEIA and by EC-IS, analyzing, in particular, some of the samples listed in Table 1 as well as
four new samples. Since we were measuring the same antibody, namely, the IgG isotype of anti-tTG,
we expressed the analyte concentration in terms of U/mL for both methods. The µg/mL values
determined by EC-IS were indeed transformed into U/mL by using the value 5.5 as a conversion
factor, calculated by measuring Inet changes for standard samples with known activity (in U/mL).
The relevant results are reported in Table 2.
Table 2. Anti-tTG IgG activities measured by the proposed electrochemical immunosensor (EC-IS) and
clinical fluoroenzyme immunoassay (FEIA) in human serum samples.
Serum Sample Anti-tTG IgG (U/mL)by EC-IS
Anti-tTG IgG (U/mL)
by FEIA
10,801 35 44
10,832 73 31
10,858 56 11
10,823 112 93
10,550 150 123
10,605 42 28
Sensors 2019, 19, 1233 12 of 16
Figure 9 shows the plot correlating the two data sets. Overall, a quite satisfactory agreement in
the general trend is observed, with slope of 0.92; however, a significant scattering between the data
can be observed, particularly at concentrations around 50 U/mL or lower. This evidence indicates that
the EC-IS method is promising; however, further studies are required to improve its accuracy at small
anti-tTG–IgG concentrations, as well as to set a new cut-off value based on a wider statistical basis.
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4. Conclusions
A highly sensitive NEE-based electrochemical immunosensor was developed and evaluated
for the determination of the IgG anti-tTG isotype involved in celiac disease. This is the first report
demonstrating the application of arrays of nanoelectrodes as a platform for the purely electrochemical
detection of CD biomarkers. The use of a smart biomolecule immobilization approach, where the
capture antigen is selectively immobilized on the PC component of the Au NEEs, helped us to retain
the desirable advantages of nanoelectrode ensembles, such as high S/N ratio. Moreover, the absence
of any surface pretreatment step of the transducer for biorecognition element immobilization reduces
the analytical steps and the reagents required, which is advantageous for transforming the proposed
protocol to practical applications.
The results presented in this work confirm the applicability of NEEs for the reliable detection
of a disease biomarker, with a low detection limit of 1.8 ng mL−1. In the new biosensor design,
the use of a redox mediator in the electrolyte solution is mandatory for achieving a high level of
sensitivity. We note that a large proportion of the reporter label is relatively far (approximately up to
200 nm) from the surface of the nanodisk electrodes where the electrochemical signal is generated;
this notwithstanding, they are reached by the mediator since NEEs operate under a total overlap
diffusion regime, with the thickness of the diffusion layer in the time frame of the experiment being
smaller than the hemi-distance between the nanoelectrodes. The immunosensor is able to detect
the disease biomarker with a wide calibration linear range (0.005 to 1 µg mL−1) and with excellent
signal reproducibility.
In addition, the presented immunosensor is capable of detecting the anti-tTG IgG biomarker in
clinical pediatric serum samples, offering strong agreement with the clinical outcome obtained for
the IgA isotype using the FEIA method. Preliminary experiments conducted on a few serum samples
showed that the new immunosensor furnishes results in basic agreement with those of the clinical FEIA
method when the IgG isotype is measured by both methods, though the accuracy of the electrochemical
immunosensor needs to be improved, particularly at low antibody concentrations. Further studies on
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larger data sets will be required in order to standardize the method, to evaluate its clinical sensitivity
and specificity, and to set an anti-tTG IgG cut-off point for the EC-IS suitable to reliably discriminate
between positive and negative serum samples. We note that further studies concerning the selectivity
of the EC-IS for anti-tTG IgG vs. anti-tTG IgA types as well as on the possibility to electrochemically
distinguish the two isotypes of this antibody are presently in progress [60].
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